Anzeigenschluss: 07.01.2026
Erscheinungstermin: 03.02.2026

Download als PDF

Fortbildungen

Schmerztherapie
H. Hofbauer et al.
Therapie tumorassoziierter Schmerzen – von medikamentös bis invasiv

Präzisionsonkologie
R. Würstlein et al.
Präzisionsonkologie, molekulares Tumorboard und translationale Programme beim metastasierten Mammakarzinom

Immuntherapie
J. Walz et al.
Peptidbasierte Immuntherapie
   
Journal Club
 
Pankreaskarzinom
Quisette P Janssen et al.
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
 
Hepatozelluläres Karzinom
Lombardi P et al.
Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study
 
Brustkrebs
Mittendorf EA et al.
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial
 
NSCLC
Ricciuti B et al.
Neoadjuvant PD-1 and PD-L1 Blockade with Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer
  
Neues aus der Forschung
 
Mammakarzinom
Tolaney M et al.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
 
DLBCL
Michot JM et al.
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial
 
Palliativmedizin
Murali S et al.
Instability in End-of-Life Goals and Preferences of Patients Who Are Seriously Ill. A Systematic Review
 
Mammakarzinom
Hurvitz SA et al.
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
 
CME Fortbildung
 
C. Rieger
Impfungen in der Onkologie
 
Onkologie aktuell
 
Kongressbericht 1
ASH-Kongress (American Society of Hematology)

Kongressbericht 2
SABCS (San Antonio Breast Cancer Symposium)

Kongressbericht 3
AIO-Herbsttagung
 

*Die Redaktion behält sich aktuelle Änderungen vor.